Prise en charge de l’asthme et de la BPCO en situation de pandémie de COVID-19 [Asthma and COPD management during the COVID-19 pandemic]
Fiche du document
6 mai 2020
- doi: 10.53738/REVMED.2020.16.692.0933
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2020.16.692.0933
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/32374540
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_798F90DE58225
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Bronchial asthmaCiter ce document
C. Daccord et al., « Prise en charge de l’asthme et de la BPCO en situation de pandémie de COVID-19 [Asthma and COPD management during the COVID-19 pandemic] », Serveur académique Lausannois, ID : 10.53738/REVMED.2020.16.692.0933
Métriques
Partage / Export
Résumé
Numerous patients with asthma or COPD are likely to be infected with SARS-CoV-2 virus. Although data is limited, patients with severe and/or uncontrolled asthma and those with COPD appear to be at increased risk of a more severe course of COVID-19 infection. Usual recommendations for management of asthma and COPD remain valid despite the ongoing epidemic. However, lung function testing and nebulisers should be performed with caution during the COVID-19 pandemic due to a potential risk of virus aerosolisation and contagion during the procedure. Particular care must be taken to identify and protect patients who are particularly vulnerable to COVID-19 infection. Asthma and COPD treatments should be pursued and adapted to ensure optimal control of the lung disease throughout the epidemic, thus reducing the risk of severe COVID-19 disease.